LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

Search

Simulations Plus Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

17.04 -1.79

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

16.91

Max

17.43

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-70M

-67M

Pardavimai

-2.1M

20M

P/E

Sektoriaus vid.

48.528

105.69

Dividendų pajamingumas

0.48

Pelno marža

-330.585

Darbuotojai

243

EBITDA

327K

5.3M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

-7.67% downside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.48%

2.37%

Kitas uždarbis

2025-12-01

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-5.6M

346M

Ankstesnė atidarymo kaina

18.83

Ankstesnė uždarymo kaina

17.04

Naujienos nuotaikos

By Acuity

50%

50%

182 / 374 reitingas Healthcare

Simulations Plus Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-12 21:55; UTC

Uždarbis

Xero Beats 1st Half Profit Expectations Despite Melio Margin Hit

2025-11-12 21:34; UTC

Uždarbis

Cisco Systems Boosts Fiscal Year Outlook as 1Q Profit, Revenue Rise

2025-11-12 23:44; UTC

Rinkos pokalbiai

Nikkei May Trade in Range Amid Caution Over U.S. Econ -- Market Talk

2025-11-12 23:38; UTC

Rinkos pokalbiai

Gold Steady Ahead of Expected End to U.S. Government Shutdown -- Market Talk

2025-11-12 23:13; UTC

Uždarbis

Samsung Fire & Marine Insurance 3Q Net Profit Largely Met FactSet-Compiled Consensus

2025-11-12 23:13; UTC

Uždarbis

Samsung Fire & Marine Insurance 3Q Net KRW538.50B Vs. Net KRW554.56B >000810.SE

2025-11-12 23:13; UTC

Uždarbis

Samsung Fire & Marine Insurance 3Q Oper Pft KRW664.06B Vs. Pft KRW717.46B >000810.SE

2025-11-12 23:13; UTC

Uždarbis

Samsung Fire & Marine Insurance 3Q Rev KRW5.732T Vs. KRW5.326T >000810.SE

2025-11-12 22:30; UTC

Rinkos pokalbiai
Uždarbis

Firefly Aerospace Sets Plan for Next Launch After Explosion -- Market Talk

2025-11-12 22:18; UTC

Uždarbis

Cisco Systems Boosts Outlook on AI-Driven Demand -- Update

2025-11-12 22:12; UTC

Rinkos pokalbiai

Bank of Canada Rate Hikes Could Start in 2H 2026 -- Market Talk

2025-11-12 22:05; UTC

Uždarbis

Pan American Silver: Campbell Succeeded Steve Busby >PAAS

2025-11-12 22:04; UTC

Uždarbis

Pan American Silver Named Scott Campbell as Operating Chief on Oct. 20

2025-11-12 22:04; UTC

Uždarbis

Pan American Silver 3Q Adj EPS 48c >PAAS

2025-11-12 22:04; UTC

Uždarbis

Pan American Silver 3Q Rev $884.4M >PAAS

2025-11-12 22:04; UTC

Uždarbis

Pan American Silver 3Q EPS 45c >PAAS

2025-11-12 22:03; UTC

Uždarbis

Manulife Financial: 3Q Book Value Per Common Shr C$26.07 >MFC.T

2025-11-12 22:02; UTC

Uždarbis

Manulife Financial 3Q Net C$1.8B >MFC

2025-11-12 22:02; UTC

Uždarbis

Manulife Financial 3Q Adj EPS C$1.16 >MFC

2025-11-12 22:02; UTC

Uždarbis

Manulife Financial 3Q EPS C$1.02 >MFC

2025-11-12 21:53; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel: Sale Strengthens Focus on Own Growth Investments

2025-11-12 21:53; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel Says Deal Subject to Indian Regulatory Approvals

2025-11-12 21:53; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel Estimates Net Profit After Tax on Sale of A$70 Million

2025-11-12 21:53; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel Expects Net Proceeds After Taxes, Fees of A$179 Million in 2H FY26

2025-11-12 21:52; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel: Tata BlueScope Steel JV a Provider of Coated, Painted Steel Products in India

2025-11-12 21:51; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel Agrees to Sell 50% Stake in Tata BlueScope Steel Joint Venture to Tata Steel

2025-11-12 21:50; UTC

Rinkos pokalbiai
Uždarbis

Basic Materials Roundup: Market Talk

2025-11-12 21:49; UTC

Uždarbis

Cisco Stock Climbs as Earnings Beat Expectations Amid Strong AI Demand -- Barrons.com

2025-11-12 21:48; UTC

Uždarbis

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares. -- Barrons.com

2025-11-12 21:40; UTC

Uždarbis

Xero Beats 1H Profit Expectations Despite Melio Margin Hit

Akcijų palyginimas

Kainos pokytis

Simulations Plus Inc Prognozė

Kainos tikslas

By TipRanks

-7.67% į apačią

12 mėnesių prognozė

Vidutinis 16 USD  -7.67%

Aukščiausias 16 USD

Žemiausias 16 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Simulations Plus Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

4 ratings

2

Pirkti

2

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

182 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat